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Introduction:  To  facilitate  introduction  of  live  attenuated  SA  14-14-2  Japanese  encephalitis  vaccine (LJEV)
into the National  Immunization  Programme  of  Sri  Lanka,  we  evaluated  the  safety  and  immunogenicity
of  co-administration  of  LJEV  and  measles  vaccine  at  9 months  of  age.  Serum  immune  responses  were
evaluated  post-vaccination  on days  28, 180,  and  365  using  JE neutralization  test and  anti-measles  IgG
ELISA.
Results:  278  infants  received  one  dose  of  LJEV  and  measles  vaccine.  Of these,  257 were  eligible  for  the
per-protocol  analysis.  On  Day  0,  14  infants  (5.5%)  were  seropositive  for JE, but  none  were  seroposi-
tive  for  measles.  At Day  28, seropositivity  rates  were  90.7%  (95%  CI,  86.4–93.9%)  for JE and  84.8%  (95%
CI,  79.8–89.0%)  for  measles.  The  geometric  mean  titer for  JE neutralizing  antibodies  was  111 (95%  CI,
90–135),  and  the geometric  mean  concentration  (GMC)  for  anti-measles  IgG  was  375  mIU/mL  (95%  CI,
351–400  mIU/mL).  Over  the next  year,  JE  neutralizing  antibody  responses  declined only  slightly,  with
seropositivity  at 87.4%  (95%  CI, 82.6–91.2%)  at  Day  365.  In contrast,  measles  antibody  levels  continued
to  increase  over  time.  Seropositivity  for anti-measles  IgG reached  97.2%  (95%  CI,  94.4–98.9%) at  Day  365,
and  the  GMC  rose  to  1202  mIU/mL  (95%  CI, 1077–1341  mIU/mL).  Co-administration  of LJEV  and  measles
vaccine  was also  safe.  Most  adverse  reactions  were  mild,  and  no  serious  adverse  events  were  related  to
study  vaccinations.
Conclusion:  The  safety  and  immunogenicity  of  LJEV  co-administered  with  measles  vaccine  in  Sri Lankan
infants  is  similar  to that  seen  in other  populations,  and our results  support  use  of LJEV  at  9 months  of age.
Live  SA  14-14-2  vaccine  is now  prequaliﬁed  by the WHO  for use  in  infants  in Asia,  and  other  countries
may  wish  to introduce  LJEV  to  combat  this  devastating  disease.
© 2014  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).. Introduction
Japanese encephalitis (JE) virus is an arbovirus that causes a dev-
stating neurological disease resulting in high rates of mortality or
eurologic sequelae. The severity of sequelae, together with the
olume of cases, makes JE an important cause of encephalitis [1,2].
∗ Corresponding author at: PATH, Mail: PO Box 900922, Seattle, WA 98109, USA.
el.: +1 206 285 3500; fax: +1 206 285 6619.
E-mail address: cvictor@path.org (J.C. Victor).
ttp://dx.doi.org/10.1016/j.vaccine.2014.06.036
264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article unThe disease is endemic across temperate and tropical zones of Asia,
and because of its zoonotic cycle, eradicating JE from the environ-
ment is unrealistic. Universal childhood vaccination is essential for
disease control.
In Sri Lanka, immunization against JE began in 1988. By
2006, two types of JE vaccines were available for use in Sri
Lanka—inactivated mouse brain-derived vaccine and live attenu-
ated SA-14-14-2 JE vaccine (LJEV). Only the inactivated vaccine
was being used in the country’s public-sector immunization pro-
gram. Concern in Japan over a rare but potentially dangerous
adverse event associated with a mouse brain-derived vaccine led
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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he manufacturer in Japan to discontinue production in 2005, thus
imiting global supply of inactivated JE vaccines and raising costs
or remaining inactivated vaccines.
In August of 2006, the World Health Organization stated in its
osition paper on Japanese encephalitis vaccines that the mouse
rain-derived vaccine should be replaced by a new generation of JE
accines [3]. For Sri Lanka, switching to the less expensive LJEV was
stimated in 2006 to save the National Immunization Programme
NIP) between US$8.6 and $8.9 million annually in direct vaccine
osts alone. To generate local immunogenicity and safety data to
uide policy for potential use of LJEV in Sri Lanka’s NIP, the Ministry
f Healthcare and Nutrition, in cooperation with PATH, initiated the
urrent study.
. Methods
.1. Study design and population
This open label, non-randomized, single-arm trial was designed
o evaluate the immunogenicity and safety of the co-administration
f LJEV and measles vaccine among infants in order to facilitate
ntroduction of LJEV into the Sri Lankan NIP at 9 months of age.
he study was conducted from July 2007 to October 2008 in three
eri-urban health divisions of low JE endemicity in the District of
olombo. Healthy infants 9 months of age (plus or minus 2 weeks)
ho could be adequately followed for safety and who  could attend
ll scheduled study visits were eligible. Infants with a history of
easles or Japanese encephalitis (or major symptoms of either dis-
ase), or a history of previous receipt of any vaccine against these
iseases, were excluded. Non-study vaccinations were restricted
o between 2 weeks prior to enrollment until 28 days after study
nrollment.
.2. Study vaccines
At enrollment, all eligible participants were administered one
ose of LJEV (SA 14-14-2, Chengdu Institute of Biological Products
CDIBP], Chengdu, China; batch 200611A078-1) subcutaneously in
he right brachium and one dose of measles vaccine live, atten-
ated (Serum Institute of India, Ltd, Pune, India; batch EU3244)
ubcutaneously in the left brachium.
.3. Primary and secondary outcomes
.3.1. Immunogenicity
Blood serum was collected immediately before administration
f study vaccines and approximately 28 days and 1 year later. After
tudy initiation, the protocol was amended to request an addi-
ional blood specimen at six months post-co-administration from
dditionally consented participants.
Primary immunogenicity objective outcomes were the pro-
ortion of subjects with demonstrated seropositivity for JE and
easles at 28 days post-co-administration. Serum neutralizing
ntibodies to the Bejing-1 JE strain were measured by plaque reduc-
ion neutralization test (PRNT) where the neutralizing titer was
easured as the inverse dilution at which plaque counts were
educed by 50%. Seropositivity for JE was then deﬁned as a neu-
ralizing antibody titer of ≥1:10, as recommended by the WHO
4]. Serum anti-measles immunoglobulin class G (IgG) antibodies
ere measured by enzyme-linked immunosorbent assay (ELISA)
Serion ELISA classic Measles Virus IgG, Serion GmbH, Würzburg,
ermany). Seropositivity for measles was deﬁned per the manufac-
urer’s instruction as an antibody concentration of >200 mIU/mL;
borderline” was  150–200 mIU/mL.
Secondary immunogenicity outcomes included the geomet-
ic mean titer (GMT) of serum neutralizing antibody to JE and 32 (2014) 4751–4757
the geometric mean concentration (GMC) of anti-measles IgG
at 28 days post-co-administration of study vaccines. Additional
secondary objectives were immunogenicity at 6 months post-co-
administration and at 1 year post-co-administration. In a separate
post-hoc analysis, immunogenicity was  also analyzed counting as
seropositive all infants with “borderline” anti-measles IgG concen-
trations.
2.4. Safety
All adverse reactions and adverse events were captured from
the time of co-administration of study vaccines until 28 days later.
Serious adverse events (SAEs)—as deﬁned by ICH GCP and with
the additional criterion of “important medical events that may
not result in death, be life threatening, or require hospitalization
may  be considered SAEs when, based upon appropriate medical
judgment, may  jeopardize the subject and may  require medical or
surgical intervention to prevent one of the outcomes listed by ICH
GCP”—occurring at any time during the study were further docu-
mented.
During the 7 days post-co-administration of study vaccines par-
ents completed diary cards for solicited and unsolicited events;
parents were given speciﬁc grading scales for solicited events
and a generic grading scale to apply to unsolicited events. Study
physicians visited the homes of study subjects 2 or 3 days post-
vaccination to check that completion of diary cards was  proceeding
well and to assist parents with any questions or problems. Addi-
tional unsolicited events were captured through parental interview
and graded by study physicians at the 28-day study clinic visit.
After the 28-day study clinic visit, participants were visited or tele-
phoned monthly by trained physicians until the end of the study to
identify only SAEs. SAEs were graded for severity using the generic
grading scale for unsolicited events.
2.5. Statistical analyses
The study was designed to estimate simultaneously seroposi-
tivity for JE and measles antibodies 28 days post-vaccination. The
primary analysis of immunogenicity was based on the per-protocol
subject population. Seropositivity rates and corresponding exact
95% conﬁdence intervals (CIs) were calculated based on the bino-
mial distributions of study outcomes. GMTs and corresponding 95%
conﬁdence intervals were calculated based on the normal distri-
butions. For calculations of JE GMTs, titers less than the limit of
detection were assigned a value of 1:5.
We  assumed the Day 28 post-co-administration seropositivity
would be 90% [5] for JE and 95% [6] for measles. Under these
assumptions, a sample size of 249 evaluable subjects was required
to demonstrate with at least 80% power that the observed seroposi-
tivity rate for JE antibodies is greater than 80% and that the observed
seropositivity rate for measles antibodies is greater than 90%, using
one-sided signiﬁcance levels of 0.025. We  planned to consent up to
312 infants to allow for up to 10% exclusion during screening and
10% loss to follow-up.
2.6. Ethics
At the end of the study, any child who had not successfully
seroconverted for JE and/or measles was  offered revaccination free
of cost. The study was  approved by the University Of Colombo Fac-
ulty Of Medicine Ethical Review Committee and PATH’s Research
Ethics Committee, USA. Written informed consent was  obtained
from parents or guardians of all participants. The study was
conducted in accordance with the principles of the Declaration of
Helsinki and in compliance with the International Conference on
P.R. Wijesinghe et al. / Vaccine 32 (2014) 4751–4757 4753
Table  1
Immunogenicity results. Seropositivity and geometric mean titers and concentra-
tions of JE neutralizing antibodies and anti-measles IgG among study subjects in the
per-protocol population.
Neutralizing antibody to JE
Time
post-vaccination
Proportion seropositivea Geometric mean
titer (GMT)
Frequency Percent (95% CI)
Day 0 14/257 5.5 (3.0–9.0) 5.5 (5.2–5.8)
Day 28 233/257 90.7 (86.4–93.9) 110.6 (90.3–135.4)
6  months 202/243 83.1 (77.8–87.6) 68.3 (55.9–83.4)
1  year 221/253 87.4 (82.6–91.2) 75.5 (62.2–91.6)
Anti-measles IgG
Time
post-vaccination
Proportion seropositiveb Geometric mean
concentration (GMC)
Frequency Percent (95% CI)
Day 0 0/257 0.0 (0.0–1.4) 20.5 (18.4–22.8)
Day 28 218/257 84.8 (79.8–89.0) 374.9 (351.0–400.4)
6  months 229/243 94.2 (90.5–96.8) 697.8 (634.0–768.0)
1  year 246/253 97.2 (94.4–98.9) 1201.7 (1076.7–1341.3)
a Seropositivity deﬁned as a titer of ≥1:10.
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Fig. 1. By-subject anti-measles IgG concentrations at 28 days, 6 months and 1 year
post-vaccination with measles vaccine and LJEV among subjects seronegative or
borderline at Day 28. The dashed line is located at the threshold for anti-measles IgG
[95% CI, 91.5–97.3%]) (Table 2).
Table 2
Immunogenicity results. Seropositivity of anti-measles IgG among study subjects in
the per-protocol population when counting borderline results as seropositive.
Anti-measles IgG
Time post-vaccination Proportion Seropositivea
Frequency Percent (95% CI)
Day 0 0/257 0.0 (0.0–1.4)
Day 28 244/257 94.9 (91.5–97.3)Seropositivity deﬁned per manufacturer’s instruction as a concentration of
200 mIU/mL. At Day 28, 26 subjects were borderline and counted as seronegative.
o  subjects were borderline at Day 180 or Day 365.
armonization’s (ICH) Good Clinical Practice (GCP) guidelines [7].
he trial was registered with ClinicaTrials.gov as NCT00463684.
. Results
.1. Study subjects
Of 299 infants screened at enrollment, 278 were determined to
e eligible for participation, provided a pre-vaccination blood spec-
men, and received LJEV and measles vaccine (16 did not meet study
nclusion criteria and 5 did not provide pre-vaccination blood spec-
mens). All vaccinated subjects were included in safety analyses. Of
hose vaccinated, 53.2% were female and 93.9% were of Sinhalese
thnicity; their average age was 9.2 months (standard deviation,
.3 months). After completion of the study, 257 participants were
etermined to meet criteria for entry into the per-protocol analysis
f immunogenicity at 28 days weeks post-co-administration with
tudy vaccines (13 were found to have been out of range for age
t inclusion, 4 did not have the Day 28 blood specimen collected
ithin range, and 4 were not able to provide sera at Day 28). A
otal of 274 subjects (98.6%) were followed to 1 year of age and
ompleted the study (1 voluntarily withdrew participation and 3
ere lost to follow-up), thus providing 12 months of safety data
ost-vaccination.
.2. Immunogenicity
Overall, infants in the study responded well to both LJEV and
easles vaccine. Immunogenicity of LJEV was high, with seroposi-
ivity 28 days post-co-administration at 90.7% (95% CI, 86.4–93.9%)
Table 1). Seropositivity for JE was maintained near this level for
s long as 1 year (87.4% [95% CI, 82.6–91.2%]). The GMT  for JE neu-
ralizing antibodies was 111 (95% CI, 90–135), well above generally
ccepted protective levels and declining only modestly to 76 (95%
I, 62–92) 1 year post-vaccination.
The seroresponse to measles vaccine was also high at 28 days
ost-co-administration (84.8% [95% CI 79.8–89.0%]) (Table 1). The
roportion of enrolled infants responding to measles vaccine then
ontinued to rise during the study, peaking at 97.2% (95% CI
4.4–98.9%) at 1 year post-vaccination. This apparent continuedseropositivity (200 mIU/mL) deﬁned by the ELISA kit. Subjects with missing blood
specimens at 6 months or 1 year post-vaccination are not included in this illustration.
development of the seroresponse to measles vaccine was mirrored
by the GMCs for measles at each time point, rising from 375 mIU/mL
(95% CI 351–400 mIU/mL) at 28 days post-co-administration to
1202 mIU/mL (95% CI 1077–1341 mIU/mL) at 1 year.
To better characterize the apparently long time-course for the
development of the immune response to measles vaccine, we
examined the anti-measles IgG level in subjects’ serial specimens.
Among all subjects with paired serum specimens for any two
time points post-vaccination, 85% had measured increases in anti-
measles IgG between 28 days and 6 months post-vaccination, 85%
had measured increases between 6 months and 1 year, and 94% had
increases from 28 days to 1 year. Among those with an increase
between any two  time points post-vaccination, in 51% of these the
concentration more than doubled between 28 days and 6 months
post-vaccination, in 48% it more than doubled between 6 months
and 12 months, and in 82% it more than doubled from 28 days to
12 months. Further, among those seronegative or borderline at Day
28 post-vaccination, nearly all such subjects developed seroposi-
tive levels by the end of the study (Fig. 1). Of subjects seronegative
for measles antibodies at 1 month post-vaccination, 40% and 83%
had become seropositive by 6 months and 1 year post-vaccination,
respectively; of subjects borderline at 1 month post-vaccination,
87% and 96% had become seropositive by 6 months and 1 year
post-vaccination, respectively. If subjects with measles responses
borderline (150–200 mIU/mL) were considered as seroresponders,
then the seropostivity rate at Day 28 would be even higher (94.9%6  months 229/243 95.9 (92.6–98.0)
1  year 246/253 97.2 (94.4–98.9)
a Seropositivity deﬁned as a concentration of ≥150 mIU/mL (includes those “bor-
derline”).
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.3. Safety
Of the 278 infants vaccinated with both LJEV and measles
accine and included in safety summaries, none experienced an
dverse reaction within 30 minutes of vaccination. During the 7
ays following vaccination, solicited local reactions were most fre-
uent during the ﬁrst three days post-co-administration and were
imilar by site of injection of LJEV (right arm) and measles vac-
ine (left arm) (Table 3). No solicited local reaction was graded as
evere. Solicited systemic reactions were also more frequent during
he ﬁrst three days post-co-administration. During the ﬁrst three
ays post-vaccination, four subjects (1.4%) had solicited systemic
eactions graded as severe—two with diarrhea, one with vomiting
nd one with insomnia. During the subsequent four days post-co-
dministration, two subjects (0.7%) had solicited systemic reactions
raded as severe—both with diarrhea. During Days 0 to 3, parents
ecorded unsolicited reactions in 20 subjects (7.2%) and during days to 7, parents recorded unsolicited reactions in 25 subjects (9.0%).
nly one of these, “a warm head,” was recorded, inexplicably, as
evere by the parent. At the Day 28 study visit, parents reported
n additional 234 unsolicited adverse events among 122 subjects
able 3
ummary of solicited and unsolicited adverse reactions and adverse events during the pe
Solicited local reactions Severity Days 0–3 
LJEV Meas
n % (95% CI) n 
Any Any severity 34 12.2 (8.6, 16.7) 27 
Grade 3 0 0.0 (0.0, 1.3) 0 
Erythema Any severity 11 4.0 (2.0, 7.0) 11 
Grade 3 0 0.0 (0.0, 1.3) 0 
Induration Any severity 7 2.5 (1.0, 5.1) 6 
Grade  3 0 0.0 (0.0, 1.3) 0 
Pain  Any severity 25 9.0 (5.9, 13.0) 21 
Grade  3 0 0.0 (0.0, 1.3) 0 
Solicited systemic reactions Severity Days 0–3 
n 
Any Any severity 105 
Grade 3 4 
Fever Any severity 21 
Grade 3 0 
Anorexia Any severity 52 
Grade  3 0 
Crying Any severity 56 
Grade 3 0 
Diarrhea Any severity 27 
Grade 3 2 
Tiredness Any severity 32 
Grade 3 0 
Insomnia Any severity 33 
Grade 3 1 
Irritability Any severity 17 
Grade 3 0 
Vomiting Any severity 17 
Grade 3 1 
Unsolicited reactions Severity Days 0–3 
n 
Any Any severity 20 
Grade 3 1a
a Reported by parent/guardian as “warm head”. 32 (2014) 4751–4757
(43.9%) (Table 4). Only two  of these events (<1%), both diarrheal
episodes, were graded as severe.
Fifty-four serious adverse events were reported among 45 sub-
jects during the 12-month course of the study (Table 5). All SAEs
were considered by site investigators to be unrelated to study inter-
ventions. No SAE resulted in death, and all SAEs resolved without
major sequelae.
4. Discussion
This study was  conducted by the Ministry of Healthcare and
Nutrition of Sri Lanka to inform a policy decision on whether
to transition the JE vaccine used in Sri Lanka’s NIP from the
mouse-brain inactivated vaccine to LJEV. In this open-label trial of
LJEV co-administered with measles vaccine to Sri Lankan infants,
measles vaccine and LJEV were well-tolerated and immunogenic
when administered concomitantly to infants at 9 months of age.
Based on data from this study, combined with the broader body
of evidence available globally on LJEV, the Sri Lankan government
ﬁrst introduced a single dose of LJEV into its national immuniza-
tion program on July 1, 2009, giving LJEV at 12 months of age. With
riod 7 days post-vaccination.
Days 4–7
les vaccine LJEV Measles vaccine
% (95% CI) n % (95% CI) n % (95% CI)
9.7 (6.5, 13.8) 2 0.7 (0.1, 2.6) 1 0.4 (0.0, 1.3)
0.0 (0.0, 1.3) 0 0.0 (0.0, 1.3) 0 0.0 (0.0, 1.3)
4.0 (2.0, 7.0) 1 0.4 (0.0, 2.0) 1 0.4 (0.0, 2.0)
0.0 (0.0, 1.3) 0 0.0 (0.0, 1.3) 0 0.0 (0.0, 1.3)
2.2 (0.8, 4.6) 0 0.0 (0.0, 1.3) 0 0.0 (0.0, 1.3)
0.0 (0.0, 1.3) 0 0.0 (0.0, 1.3) 0 0.0 (0.0, 1.3)
7.6 (4.7, 11.3) 1 0.4 (0.0, 2.0) 0 0.0 (0.0, 1.3)
0.0 (0.0, 1.3) 0 0.0 (0.0, 1.3) 0 0.0 (0.0, 1.3)
Days 4–7
% (95% CI) n % (95% CI)
37.8 (32.1, 43.8) 55 19.8 (15.3, 25.0)
1.4 (0.4, 3.6) 2 0.7 (0.1, 2.6)
7.6 (4.7, 11.3) 14 5.0 (2.8, 8.3)
0.0 (0.0, 1.3) 0 0.0 (0.0, 1.3)
18.7 (14.3, 23.8) 32 11.5 (8.0, 15.9)
0.0 (0.0, 1.3) 0 0.0 (0.0, 1.3)
20.1 (15.6, 25.4) 18 6.5 (3.0, 10.0)
0.0 (0.0, 1.3) 0 0.0 (0.0, 1.3)
9.7 (6.5, 13.8) 19 6.8 (4.2, 10.5)
0.0 (0.0, 1.3) 2 0.0 (0.0, 1.3)
11.5 (8.0, 15.9) 11 4.0 (2.0, 7.0)
0.0 (0.0, 1.3) 0 0.0 (0.0, 1.3)
11.9 (8.3, 16.3) 15 5.4 (3.1, 8.7)
0.4 (0.0, 2.0) 0 0.0 (0.0, 1.3)
6.1 (3.6, 9.6) 10 3.6 (1.7, 6.5)
0.0 (0.0, 1.3) 0 0.0 (0.0, 1.3)
6.1 (3.6, 9.6) 6 2.2 (0.8, 4.6)
0.4 (0.0, 2.0) 0 0.0 (0.0, 1.3)
Days 4–7
% (95% CI) n % (95% CI)
7.2 (4.5, 10.9) 25 9.0 (5.9, 13.0)
0.4 (0.0, 2.0) 0 0.0 (0.0, 1.3)
P.R. Wijesinghe et al. / Vaccine
Table  4
Adverse events among subjects days 8–28 post-co-administration with LJEV and
measles vaccine (safety population; n = 278 subjects).
System organ class Subjectsa Events
Preferred term n % n %
Any adverse event 122 43.9% 234 100.0%
Eye disorders 1 0.4% 1 0.4%
Conjunctivitis 1 0.4% 1 0.4%
Gastrointestinal disorders 17 6.1% 24 10.3%
Anal skin tags 1 0.4% 1 0.4%
Constipation 1 0.4% 1 0.4%
Diarrhoea 12 4.3% 13 5.6%
Vomiting 8 2.9% 9 3.8%
General disorders and
administration site conditions
39 14.0% 40 17.1%
Gait disturbance 1 0.4% 1 0.4%
Pyrexia 38 13.7% 39 16.7%
Immune system disorders 1 0.4% 1 0.4%
Food allergy 1 0.4% 1 0.4%
Infections and infestations 68 24.5% 86 36.8%
Acarodermatitis 1 0.4% 1 0.4%
Bacterial infection 1 0.4% 1 0.4%
Bronchiolitis 1 0.4% 1 0.4%
Bronchitis 1 0.4% 1 0.4%
Bronchopneumonia 1 0.4% 1 0.4%
Dysentery 1 0.4% 1 0.4%
Ear  infection 1 0.4% 1 0.4%
Eczema infected 1 0.4% 1 0.4%
Gastroenteritis 11 4.0% 12 5.1%
Gastroenteritis viral 1 0.4% 1 0.4%
Impetigo 1 0.4% 1 0.4%
Infection 1 0.4% 1 0.4%
Lower respiratory tract infection 10 3.6% 10 4.3%
Nasopharyngitis 34 12.2% 35 15.0%
Otitis media acute 1 0.4% 1 0.4%
Rash pustular 1 0.4% 1 0.4%
Subcutaneous abscess 1 0.4% 1 0.4%
Tonsillitis 1 0.4% 1 0.4%
Upper respiratory tract infection 3 1.1% 3 1.3%
Urinary tract infection 2 0.7% 2 0.9%
Viral infection 8 2.9% 9 3.8%
Injury, poisoning and procedural
complications
4 1.4% 4 1.7%
Concussion 1 0.4% 1 0.4%
Ear  injury 1 0.4% 1 0.4%
Laceration 1 0.4% 1 0.4%
Thermal burn 1 0.4% 1 0.4%
Nervous system disorders 4 1.4% 5 2.1%
Febrile convulsion 3 1.1% 4 1.7%
Headache 1 0.4% 1 0.4%
Psychiatric disorders 1 0.4% 1 0.4%
Crying 1 0.4% 1 0.4%
Reproductive system and breast
disorders
1 0.4% 1 0.4%
Genital labial adhesions 1 0.4% 1 0.4%
Respiratory, thoracic and
mediastinal disorders
50 18.0% 64 27.4%
Asthma 1 0.4% 1 0.4%
Cough 46 16.5% 46 19.7%
Productive cough 1 0.4% 1 0.4%
Rhinorrhoea 8 2.9% 8 3.4%
Wheezing 8 2.9% 8 3.4%
Skin  and subcutaneous tissue
disorders
7 2.5% 7 3.0%
Dermatitis allergic 1 0.4% 1 0.4%
Rash 3 1.1% 3 1.3%
Rash erythematous 1 0.4% 1 0.4%
t
M
a
i
mRash papular 2 0.7% 2 0.9%
a Each subject is counted once per “system organ class preferred term”.
he introduction of MMR  vaccine at 12 months of age in 2011, the
inistry of Health then moved the single dose of LJEV to be givent 9 months of age.
The results of this study contribute to our overall understand-
ng of the immune responses to post-co-administered LJEV and
easles vaccine in young infants. Immunogenicity, as measured 32 (2014) 4751–4757 4755
by seropositivity rates 28 days post-vaccination was found to be
high in this study for both LJEV and MV  when the vaccines were
administered concurrently in subjects 9 months of age. The study’s
prespeciﬁed criterion for JE (lower bound of the 95% CI of >80%)
was met, but the more stringent criterion for measles (lower bound
of the 95% CI of >90%) was not, at least when strictly adhering to
the anti-measles IgG ELISA manufacturer’s deﬁnition of seropositi-
vity.
Our ﬁnding of an apparent long time-course for development
of an immune response to measles vaccine deserves further exam-
ination. Because measles-containing vaccines were administered
through a very strong public health system in Sri Lanka and because
the Ministry Of Healthcare and Nutrition both oversees delivery
of measles vaccine in the public sector and led this study, it is
highly unlikely that any child in the current study received an addi-
tional measles vaccination during the course of the study without
the study team having record of such immunization. Additionally,
there were no supplementary immunization activities (vaccina-
tion campaigns) for measles conducted in Sri Lanka during the
period of the trial. Ongoing transmission of measles is unlikely to
have contributed to the increases in seropositivity, as Sri Lanka has
maintained very high rates of measles vaccination among infants
since 2000 [8], and there were no known/reported outbreaks of
measles in the District of Colombo during the study period. And
ﬁnally, unrecognized measles transmission would have had to
occur at very high community attack rates in infants (e.g. 90%), as
we found long-term increases in anti-measles IgG after 28 days
post-vaccination in nearly all infants in the study. Few studies have
prospectively measured measles antibody responses so long after
vaccination with a single dose of measles vaccine at 9 months of age,
but studies in the Gambia [9,10] (measles vaccine co-administered
with yellow fever vaccine) and Malawi [11] (measles vaccine given
alone) have made similar ﬁndings of continually increasing measles
immune responses at 9–15 months post-vaccination in the absence
of identiﬁed measles outbreaks and with “no explanation for this
trend” [10].
Regarding our ﬁndings for the immune response to JE, these
results are similar to those obtained in a study among 9-month-
old infants in the Philippines in which measles vaccine and LJEV
were administered concomitantly [5,12]. The seropositivity to JE
measured at one month was nearly identical in the Sri Lankan and
Philippine infants (90.7% vs 90.5%, respectively), although the JE
GMTs were somewhat lower in the Sri Lankan infants (111 vs 155,
respectively). The signiﬁcance of the lower GMTs are uncertain,
given that GMTs in both populations are well above the WHO-
recommended threshold of protection of a 1:10 dilution in a 50%
PRNT assay [4]. It is reassuring that 1 year following administration
of the vaccine, JE antibody concentrations were well-maintained
in Sri Lankan children. In studies in infants and young children
that have measured the response to LJEV alone, seropositivity rates
post-vaccination have ranged from 86% in Bangladesh [13], to 92%
in the Philippines [5], to 95% in Thailand [14] and 96% in Korea [15].
A key limitation of this study was that there was not a control
group followed in parallel to strengthen interpretation of immuno-
genicity and safety. Additionally, we measured seropositivity for
measles antibodies using ELISA, which does speciﬁcally measure
neutralizing antibodies; only results from PRNT for measles are
considered truly indicative of seroprotective responses to measles
[16].
This study demonstrated an excellent reactogenicity proﬁle for
LJEV and MV  when given concomitantly to infants. The majority of
local and systemic reactions were mild and transient. There were
no SAEs deemed to be related to vaccine. Results from this study
add further support to the overall safety study proﬁle of LJEV when
given alone or with measles vaccine. At their June 2013 meeting, the
Global Advisory Committee on Vaccine Safety, convened by WHO,
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Table 5
Serious adverse events among all subjects during the course of the study.
Subject Event Onset day post-vaccination Severitya
8 Constipation 2 Moderate
40  Febrile seizureb 2 Moderate
42  Acute gastroenteritis 19 Moderate
45  Traumatic soft palatal laceration 25 Moderate
27  Acute gastroenteritis 32 Moderate
17  Hot water burn 39 Moderate
44  Acute gastroenteritis 51 Moderate
35  Bronchiolitis with secondary bacterial infection 61 Moderate
7  Typical febrile convulsions 70 Moderate
29  Lower respiratory tract infection 71 Moderate
4  Acute gastroenteritis 80 Moderate
37  Fever 86 Moderate
39  Lower respiratory tract infection 87 Moderate
20  Acute gastroenteritis 89 Moderate
19  Acute gastroenteritis 93 Moderate
43  Abscess on the right buttock 102 Moderate
6  Viral fever 105 Mild
24  Urinary tract infection 106 Moderate
22  Urinary tract infection 107 Moderate
24  Acute gastroenteritis 111 Moderate
16  Viral fever 112 Moderate
32  Acute gastroenteritis 113 Moderate
38  Infected eczema over both legs 113 Moderate
28  Bronchial asthma 124 Moderate
16  Acute gastroenteritis 129 Moderate
41  Labial adhesion 129 Moderate
16  Dysentery 133 Moderate
2  Acute otitis media 139 Mild
9  Concussion 153 Mild
11  Acute gastroenteritis 162 Mild
36  Tonsilitis 166 Moderate
3  Viral gastroenteritis 175 Mild
25  Febrile convulsion 175 Moderate
25  Fever of unknown origin 183 Moderate
33  Viral fever 189 Moderate
34  Lower respiratory tract infection 195 Moderate
18  Viral fever 213 Moderate
1  Viral fever 214 Mild
31  Lower respiratory tract infection 233 Moderate
21  Lower respiratory tract infection 239 Moderate
26  Fever of unknown origin 246 Moderate
13  Viral fever 248 Moderate
37  Lower respiratory tract infection 264 Moderate
23  Viral fever 268 Moderate
5  Anal tag 286 Mild
12  Lower respiratory tract infection 300 Moderate
15  Acute gastroenteritis 302 Moderate
30  Bronchopneumonia 307 Moderate
7  Febrile ﬁts 314 Moderate
31  Right pinna laceration 314 Mild
10  Acute bronchitis with wheeze 317 Moderate
14  Antalgic gait 339 Moderate
14  Viral fever 347 Moderate
14  Viral fever with secondary bacterial conjunctivitis 362 Moderate
a Severity was graded as follows: Mild: events require minimal or no treatment and do not interfere with the child’s functioning. Moderate: events result in a low level
of  concern with therapeutic measures. Moderate events may  cause some interference with functioning. Severe:  events interrupt the child’s functioning and may require
systemic drug therapy or other treatment. Severe events are usually incapacitating. Life threatening: any adverse drug experience that places the child, in the view of the
investigator, at immediate risk of death from the reaction as it occurred. (The investigator should not include a reaction that had it occurred in a more severe form, might
have  caused death.)
b The subject experiencing this event developed an elevated body temperature of 37.5 ◦C axillary on the day following study vaccination. Two  days after study vaccination,
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dhe  subject further developed cough and wheeze and was taken to see a general pra
wo  to three minutes. At this time the subject’s body temperature was  recorded 
nvestigators considered that the event was more likely to be related to a developin
eviewed updated safety information on the LJEV, including from
his study, and concluded that the LJEV has an “excellent” safety
roﬁle [17].
Many new JE vaccines have emerged on the global market in the
ast 5 years. The comparative advantages of LJEV for routine use
n public sector markets include its single dose schedule, afford-
ble price, and demonstrated effectiveness. Studies in China have
hown protective efﬁcacy of 96–98% up to 17 years after a two-
ose regimen [18]. A study from Nepal also reported protectioner whereupon the subject experienced a tonic clonic seizure lasting approximately
◦C axillary. The subject was treated and sent home without hospitalization. The
te respiratory infection than to study vaccination.
of 99.6% after a single dose given within one week of an outbreak
[19], and follow-up studies in that population have demonstrated
continued high protection (98.5%) 12–15 months after vaccination
[20] and 5 years after vaccination (96.2%) [21]. A recent study in
Nepal after mass campaigns with LJEV further demonstrates the
vaccine’s impact on substantially reducing laboratory-conﬁrmed
JE and acute encephalitis syndrome cases [22].
In addition to Sri Lanka, 10 other Asian countries have national or
subnational JE vaccine programs, of which China, India, Nepal and
accine
C
W
c
f
t
T
o
a
A
a
i
i
v
t
H
S
C
D
G
t
m
T
n
G
P
c
w
f
D
s
c
S
M
I
w
N
t
o
J
i
o
t
J
d
d
a
T
t
f
t
f
o
P
a
d
a
e
M
[
[
[
[
[
[
[
[
[
[
[
[
2007;25:5041–5.P.R. Wijesinghe et al. / V
ambodia also utilize the LJEV vaccine [2]. In October of 2013, the
HO  prequaliﬁed LJEV for procurement by United Nations agen-
ies, and in November 2013, the GAVI Alliance opened a window of
unding for Japanese encephalitis vaccine that will allow countries
o submit proposals for ﬁnancial support of JE vaccine campaigns.
hese historic decisions provide the opportunity to further the use
f JE vaccine across Asia and the Paciﬁc and provide protection to
ll children at risk of this devastating disease.
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